Key result
Subcutaneous G-CSF increases ECG ST elevation disappearance by 21% and improves collateral flow versus placebo.
Why the study?
The efficacy of G-CSF for coronary collateral growth promotion and impending myocardial salvage had not been studied.
Does subcutaneous G-CSF improve coronary collateral growth and signs of myocardial salvage in patients with chronic stable coronary artery disease?
RCT (n=52)
Double-blind
randomized
Does subcutaneous G-CSF improve coronary collateral growth and signs of myocardial salvage in patients with chronic stable coronary artery disease?
Absolute Event Rate: 21% vs 0%
p-value: p=0.0005
Short-term subcutaneous G-CSF administration significantly improves coronary collateral function and reduces signs of myocardial ischemia during balloon occlusion in patients with chronic stable coronary artery disease.
Supports G-CSF to enhance myocardial salvage in chronic CAD; extends collateral growth stimulation to randomized clinical evidence.
BACKGROUND: The efficacy of granulocyte colony-stimulating factor (G-CSF) for coronary collateral growth promotion and thus impending myocardial salvage has not been studied so far, to our best knowledge. METHODS AND RESULTS: In 52 patients with chronic stable coronary artery disease, age 62+/-11 years, the effect on a marker of myocardial infarct size (ECG ST segment elevation) and on quantitative collateral function during a 1-minute coronary balloon occlusion was tested in a randomized, placebo-controlled, double-blind fashion. The study protocol before coronary intervention consisted of occlusive surface and intracoronary lead ECG recording as well as collateral flow index (CFI, no unit) measurement in a stenotic and a > or =1 normal coronary artery before and after a 2-week period with subcutaneous G-CSF (10 microg/kg; n=26) or placebo (n=26). The CFI was determined by simultaneous measurement of mean aortic, distal coronary occlusive, and central venous pressure. The ECG ST segment elevation >0.1 mV disappeared significantly more often in response to G-CSF (11/53 vessels; 21%) than to placebo (0/55 vessels; P=0.0005), and simultaneously, CFI changed from 0.121+/-0.087 at baseline to 0.166+/-0.086 at follow-up in the G-CSF group, and from 0.152+/-0.082 to 0.131+/-0.071 in the placebo group (P<0.0001 for interaction of treatment and time). The absolute change in CFI from baseline to follow-up amounted to +0.049+/-0.062 in the G-CSF group and to -0.010+/-0.060 in the placebo group (P<0.0001). CONCLUSIONS: Subcutaneous G-CSF is efficacious during a short-term protocol in improving signs of myocardial salvage by coronary collateral growth promotion.
No takes yet. Share an insight, caveat, or question.
Meier et al. (2009) conducted an RCT in chronic stable coronary artery disease (n=52). Granulocyte colony-stimulating factor (G-CSF) vs. Placebo was evaluated on Disappearance of ECG ST segment elevation >0.1 mV (p=0.0005). Subcutaneous G-CSF significantly increased the disappearance of ECG ST segment elevation (21% vs 0%; P=0.0005) and improved collateral flow index compared to placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: